Abstract
The clinical impact of minimal residual disease detection at early time points or during follow-ups has been shown to accurately predict relapses among patients with lymphomas, mainly in follicular and diffuse large B cell lymphoma. The field of minimal residual disease testing in mantle cell lymphoma is still evolving but has great impact in determining the prognosis. Flow cytometry and polymerase chain reaction-based testing are most commonly used methods in practice; however, these methods are not sensitive enough to detect the dynamic changes that underline lymphoma progression. Newer methods using next-generation sequencing, such as ClonoSeq, are being incorporated in clinical trials. Other techniques under evolution include CAPP-seq and anchored multiplex polymerase chain reaction-based methods. This review article aims to provide a comprehensive update on the status of minimal residual disease detection and its prognostic effect in mantle cell patients. The role of circulating tumor DNA-based minimal residual disease detection in lymphomas is also discussed.
Original language | English (US) |
---|---|
Pages (from-to) | 127 |
Number of pages | 1 |
Journal | Journal of hematology & oncology |
Volume | 13 |
Issue number | 1 |
DOIs | |
State | Published - Sep 24 2020 |
Keywords
- Liquid biopsy
- Mantle cell lymphoma
- Minimal residual disease
- Next-generation sequencing
- ctDNA
ASJC Scopus subject areas
- Molecular Biology
- Hematology
- Oncology
- Cancer Research